pharmaphorum

OCTOBER 16, 2020

Patients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a new study aims to see if digital health technologies can improve their prospects. The trial – run by Boehringer Ingelheim and Yale University – will test a smart bathroom scale device that has cardiac monitoring built in, as well as an app to help patients improve their diet and lose weight and a digital assistant designed to motivate them to actively manage their health.

Communication 119

Communication Hospitals 119

Outsourcing Pharma

OCTOBER 12, 2020

Technology impacting generic drugs include artificial intelligence, telemedicine, fraud-preventing digital solutions and more, according to a report.

119

119

Pharma Marketing Network

OCTOBER 13, 2020

Below is a Q&A with Mark Bard, Co-Founder of The DHC Group, who offers his insights on the challenges COVID-19 has brought to pharma, as well as what innovation is taking place due to this full shift to digital and what lies ahead in the future. What is the most challenging aspect of COVID-19 for the industry? Mark Bard: I think the most challenging aspect of the current situation is the inability of anyone – patient, physician, payor, or pharma – to truly predict how long it will take for v

Hospitals 105

Hospitals Insurance Communication 105

Pharma Mirror

OCTOBER 14, 2020

Histoplasmosis is an inflammatory lung infection that usually occurs when a human has had contact with bird or bat droppings. Histoplasmosis is similar in symptoms to COVID-19, such as shortness of breath, fever, chest pain, and coughing. Some people who are at high-risk for histoplasmosis may also be concerned that they have contracted COVID-19. Though.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

OCTOBER 13, 2020

Ayming Group’s second annual International Innovation Barometer (IIB) has said that the international outlook for R&D is “remarkably promising” despite strong headwinds caused by COVID-19. The report reveals that R&D departments are being empowered by the creation of ‘innovation ecosystems’, new funding methods, and the deployment of technology.

115

115

Outsourcing Pharma

OCTOBER 13, 2020

The clinical-stage drug development company has kicked off testing the experimental anticancer drug Veyonda on severe patients in a Phase I trial.

105

105

indispensable health

OCTOBER 12, 2020

Pre-Interview Tips for Pharmacy Professionals | Tip #3 with Tom Alig | Vice President of Staffing at Indispensable Health Hi, I am Tom Alig, VP of Staffing with Indispensable Health. I’ve been recruiting pharmacists and pharmacy technicians since 2004, and I’ve seen the things good candidates do to separate themselves, and I’ve seen the mistakes that some candidates make.

Customer Service 52

Customer Service 52

pharmaphorum

OCTOBER 16, 2020

In the age of artificial intelligence, no trial data should be going to waste. Findacure’s Rick Thompson looks at how these technologies could bring us closer to treatments for underserved rare diseases. The repurposing of drugs is becoming more common, especially in the field of rare diseases. In the past, repurposing has mostly been driven by academics looking for new possibilities in generics.

Pharmaceutical Companies 103

Pharmaceutical Companies Pharmaceutical Companies Immunization 103

Outsourcing Pharma

OCTOBER 14, 2020

The federal government continues to offer life-sciences professionals advice and resources as they pursue treatments to help fight the COVID-19 virus.

FDA 81

FDA 81

Med Ed 101

OCTOBER 14, 2020

This might be one of my biggest pet peeves. Adding a medication when we are already doing the opposite with another medication. I had a patient a while back who was taking cholestyramine twice daily for constipation. The patient and caregivers were unclear why the patient was on it but was noting that constipation was […]. The post Pet Peeve Alert: Can We Have a Constipation Medication?

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

OCTOBER 12, 2020

Two trials will involve over 6,000 participants at sites in and outside the US

52

52

pharmaphorum

OCTOBER 14, 2020

There is growing evidence that the coronavirus may be able to re-infect patients, and a new instance of a second infection has been confirmed in the US. . It is the fifth confirmed reinfection worldwide after at least four other cases were confirmed in Belgium, the Netherlands, Hong Kong and Ecuador. The latest case was recorded in the Lancet Infectious Diseases journal and involved a 25 year-old man with no known immune disorders or underlying conditions.

Immunization 98

Immunization Hospitals 98

Outsourcing Pharma

OCTOBER 15, 2020

The pharmaceutical firmâs More to uS is a UK-centered campaign that shares stories of people living (and thriving) after a multiple sclerosis diagnosis.

82

82

Med Ed 101

OCTOBER 11, 2020

Why do patients stop taking medications? I’ve spent a lot of time and effort working with patients to improve their drug therapy, but it really doesn’t matter if they don’t actually take the medication that is best for them. Here’s a list of the most common reasons that patients stop taking their medication(s). To be […]. The post Why Do Patients Stop Taking Medications?

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharma Times

OCTOBER 12, 2020

Oral S1P receptor modulator hit both primary endpoints in a phase III trial

51

51

pharmaphorum

OCTOBER 16, 2020

Sanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after reporting that it stimulated antibodies against SARS-CoV-2 in preclinical testing. The French drugmaker’s Sanofi Pasteur vaccines division says it is planning a phase 1/2 trial of the mRNA-based vaccine, called MRT5500, before the end of the year.

Vaccines 98

Vaccines 98

Outsourcing Pharma

OCTOBER 12, 2020

Study solutions provider H? blends behavioral science, decision economics and technology to better integrate the patient voice into clinical research.

64

64

Druggist

OCTOBER 16, 2020

Several factors can impact breast milk supply with common factors including low frequency of breastfeeding, wrong latching by a baby, late start of breastfeeding, use of formula alongside breastfeeding and some drugs. Drug therapy to increase milk production is usually considered when insufficient milk is produced despite appropriate lactation support (Grzeskowiak et al, 2018).

Community Pharmacies 98

Community Pharmacies Dosage Hospitals 98

Pharma Times

OCTOBER 13, 2020

In a letter to Health Secretary Matt Hancock the RPS called for urgent action

49

49

pharmaphorum

OCTOBER 13, 2020

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. Since it was founded in 2001 the company has become one of the country’s best known biotechs thanks to its approach to designing drugs based around network biology. e-therapeutics aims to design drugs that work across several targets that drive complex diseases and its remit has ch

95

95

Outsourcing Pharma

OCTOBER 13, 2020

The clinical research site network has tapped 22-year industry veteran Karri Venn, president of research with LMC Manna, to lead the organization.

52

52

Druggist

OCTOBER 13, 2020

It is estimated that around 103,800 of people live with HIV in the UK (PHE, 2019). Estimated 17% of people with HIV are not aware of the infection (NICE, 2016), increasing the risk of passing HIV when having sex without protection. Truvada (emtricitabine/tenofovir disoproxil) is an antiviral drug used in the treatment of HIV, alone or as part of antiviral combination therapy.

Community Pharmacies 98

Community Pharmacies Documentation 98

Pharma Times

OCTOBER 13, 2020

Biologic therapy hit primary and all key secondary endpoints in phase III

49

49

pharmaphorum

OCTOBER 14, 2020

A lack of clear information on COVID risk is stopping people with long-term conditions accessing the care they need – and could be storing up problems for the future. People living with long-term health conditions have been missing vital tests and monitoring because they fear contracting the novel coronavirus. A survey carried out by the Patient Information Forum (PIF), and supported by Norgine, this summer found that almost one in three respondents had delayed accessing care during the pandemic

Health and Personal Care Stores 90

Health and Personal Care Stores Communication Hospitals 90

Outsourcing Pharma

OCTOBER 14, 2020

The pharma ingredients company has named veteran Scott Thomson, a 29-year veteran with chemicals firm BASF, to its executive leadership team.

52

52

pharmaphorum

OCTOBER 12, 2020

There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, with a record £1 billion raised in the third quarter. Latest figures from the BioIndustry Association representing the UK’s biotech and life sciences sector, showed it raised more than £1 billion in equity finance between June and August, the highest in the sector on record.

79

79

pharmaphorum

OCTOBER 12, 2020

Gastroenterologist Dr Séverine Vermeire explains how lockdowns and communication changes over COVID-19 are taking their toll on ulcerative colitis patients and how we can best support them in the new normal. In an increasingly virtual healthcare world, the value of doctor to patient communication can’t be undervalued, especially in chronic conditions like ulcerative colitis.

Communication 73

Communication Hospitals Compounding 73

pharmaphorum

OCTOBER 16, 2020

Gilead’s Veklury (remdesivir) has failed to produce an effect on hospital stay and mortality in COVID-19 patients in a large global trial, casting doubt on previous supportive study findings. The results from the World Health Organization’s large Solidarity trial are yet to be peer reviewed but were posted online on a preprint server. Interim findings from Solidarity, which involved more than 11,000 patients in more than 30 countries, contradict those from the manufacturer in a US study.

Hospitals 76

Hospitals Compounding Labelling FDA 76

pharmaphorum

OCTOBER 13, 2020

A record number of health and medtech companies have been included in the Sunday Times Sage Tech Track 100, which ranks Britain’s private tech companies. The COVID-19 pandemic has seen a boost in business for many companies involved in the health sector, and there were 12 health tech companies involved in this year’s list. This compares with just six such firms when the list began 20 years ago.

Vaccines 69

Vaccines FDA 69

pharmaphorum

OCTOBER 15, 2020

Astellas Pharma is to buy bioelectronic medical devices firm iota Biosciences in a deal worth up to $429m, building on a previous research partnership. In August last year the companies began a joint research and development agreement based around iota’s bioelectronic devices in several indications. Bioelectronics is a field that has been investigated by Google’s life sciences division Verily, which co-founded Galvani Bioelectronics with GlaxoSmithKline in 2016.

Communication 64

Communication 64

pharmaphorum

OCTOBER 14, 2020

Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom of the sleep disorder that can cause total body collapse. Wakix (pitolisant) was first approved in August 2019 for treatment of excessive sleepiness in adults with narcolepsy. It is the only FDA-approved drug to treat cataplexy associated with narcolepsy not scheduled as a controlled substance by the US Drug Enforcement Administration.

Labelling 64

Labelling Controlled Substances FDA 64

pharmaphorum

OCTOBER 14, 2020

US startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK for its expertise in applying artificial intelligence to drug discovery. Waltham, Massachusetts-based Blue Oak – led by neurobiologist and former Eli Lilly and Sunovion executive Tom Large – will work with Exscientia on new classes of neuropsychiatric drugs, with a focus on “bispecific” small molecules that can interact with two drug targets at once.

FDA 59

FDA 59

pharmaphorum

OCTOBER 12, 2020

It was supposed to be at the heart of the UK government’s fight against coronavirus – but after months of delays it has emerged that the NHS COVID-19 app has sent just one alert over a potentially infected venue. Despite rapidly rising numbers of cases, especially in cities in the north of England, Sky News said the app has sent one alert about a coronavirus outbreak at a venue since its launch two weeks ago.

59

59

pharmaphorum

OCTOBER 15, 2020

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion. Massachusetts-based Disarm is focused on treatments for diseases caused by axonal degeneration, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis. Disarm has discovered novel, potent SARM1 inhibitors and is advancing them into preclinical development for diseases including peripheral neuropathy as

65

65